Literature DB >> 7582258

Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line.

M K Jakobsen1, N P Restifo, P A Cohen, F M Marincola, L B Cheshire, W M Linehan, S A Rosenberg, R B Alexander.   

Abstract

We studied major histocompatibility complex (MHC) class I expression in 12 tumor cell culture lines established from patients with metastatic renal cell carcinoma (RCC). In one of these cell culture lines, UOK 123, we found no surface expression of beta 2-microglobulin (beta 2m) and MHC class I by flow cytometry. Immunofluorescence staining using three different monoclonal antibodies to beta 2m revealed no detectable beta 2m in the endoplasmic reticulum (ER), Golgi apparatus, cytoplasm, or on the cell surface. There was no evidence of folded class I molecules inside or on the surface of the cells; however, the ER stained intensively for unfolded class I molecules. Transient expression of beta 2m by UOK 123 after infection with a recombinant vaccinia virus containing the gene for beta 2m resulted in normal expression of both beta 2m and class I (HLA-A, B, C) determinants assessed by flow cytometry analysis. No expression of class I or beta 2m was seen with the recombinant vaccinia vector carrying a control gene. The inability of class I molecules to reach the cell surface is due to the requirement of beta 2m for proper folding and presentation of the class I MHC complex. The failure to assemble and express MHC class I complex on the cell surface renders these cells incapable of antigen presentation to cytotoxic T cells and provides a mechanism for escape from immune recognition by the tumor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7582258      PMCID: PMC2556861          DOI: 10.1097/00002371-199505000-00004

Source DB:  PubMed          Journal:  J Immunother Emphasis Tumor Immunol        ISSN: 1067-5582


  29 in total

1.  Association of class I major histocompatibility heavy and light chains induced by viral peptides.

Authors:  A Townsend; C Ohlén; J Bastin; H G Ljunggren; L Foster; K Kärre
Journal:  Nature       Date:  1989-08-10       Impact factor: 49.962

2.  Assembly of MHC class I molecules analyzed in vitro.

Authors:  A Townsend; T Elliott; V Cerundolo; L Foster; B Barber; A Tse
Journal:  Cell       Date:  1990-07-27       Impact factor: 41.582

3.  Tumor-specific cytolysis by lymphocytes infiltrating human melanomas.

Authors:  S L Topalian; D Solomon; S A Rosenberg
Journal:  J Immunol       Date:  1989-05-15       Impact factor: 5.422

4.  Defective antigen presentation by human melanoma cell lines cultured from advanced, but not biologically early, disease.

Authors:  M A Alexander; J Bennicelli; D Guerry
Journal:  J Immunol       Date:  1989-06-01       Impact factor: 5.422

5.  Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products.

Authors:  N J Stam; H Spits; H L Ploegh
Journal:  J Immunol       Date:  1986-10-01       Impact factor: 5.422

6.  Reduced expression of HLA class I and II antigens in colon cancer.

Authors:  C J McDougall; S S Ngoi; I S Goldman; T Godwin; J Felix; J J DeCosse; B Rigas
Journal:  Cancer Res       Date:  1990-12-15       Impact factor: 12.701

7.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors:  S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

8.  Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression.

Authors:  C M D'Urso; Z G Wang; Y Cao; R Tatake; R A Zeff; S Ferrone
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

9.  Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.

Authors:  A Belldegrun; L M Muul; S A Rosenberg
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

10.  Immunohistochemical detection of major histocompatibility complex antigens and quantitative analysis of tumour-infiltrating mononuclear cells in renal cell cancer.

Authors:  Y Tomita; T Nishiyama; M Fujiwara; S Sato
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

View more
  6 in total

Review 1.  CAR-T Cell Therapy for Lymphoma.

Authors:  Carlos A Ramos; Helen E Heslop; Malcolm K Brenner
Journal:  Annu Rev Med       Date:  2015-08-26       Impact factor: 13.739

2.  Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: a retrospective analysis.

Authors:  Sumanta K Pal; Jeremy O Jones; Courtney Carmichael; Junmi Saikia; Joanne Hsu; Xueli Liu; Robert A Figlin; Przemyslaw Twardowski; Clayton Lau
Journal:  Urol Oncol       Date:  2012-05-17       Impact factor: 3.498

Review 3.  Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.

Authors:  Carlos A Ramos; Gianpietro Dotti
Journal:  Expert Opin Biol Ther       Date:  2011-04-04       Impact factor: 4.388

4.  Total HLA class I loss in a sarcomatoid renal carcinoma cell line caused by the coexistence of distinct mutations in the two encoding beta2-microglobulin genes.

Authors:  Chin-Hsuan Hsieh; Ya-Jan Hsu; Chien-Chung Chang; Hsin-Chun Liu; Kun-Lung Chuang; Cheng-Keng Chuang; See-Tong Pang; Kenichiro Hasumi; Soldano Ferrone; Shuen-Kuei Liao
Journal:  Cancer Immunol Immunother       Date:  2008-08-15       Impact factor: 6.968

5.  Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling.

Authors:  Scott Wilkie; May C I van Schalkwyk; Steve Hobbs; David M Davies; Sjoukje J C van der Stegen; Ana C Parente Pereira; Sophie E Burbridge; Carol Box; Suzanne A Eccles; John Maher
Journal:  J Clin Immunol       Date:  2012-04-17       Impact factor: 8.317

Review 6.  Advances in MUC1-Mediated Breast Cancer Immunotherapy.

Authors:  Zhifeng Li; Dazhuang Yang; Ting Guo; Mei Lin
Journal:  Biomolecules       Date:  2022-07-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.